AlphaStocks
4.3
Weak

SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Health Care / Pharmaceuticals

S&P SmallCap 600

$51.36

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

#781out of 1127 in Health Care

Is SUPERNUS PHARMACEUTICALS, INC. a Good Investment in 2026?

SUPERNUS PHARMACEUTICALS, INC. (SUPN) scores 4.3 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Lynch model rates SUPERNUS PHARMACEUTICALS, INC. as Attractive. However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 97%). SUPERNUS PHARMACEUTICALS, INC. currently trades above its estimated fair value of $33, suggesting limited upside at current prices. SUPERNUS PHARMACEUTICALS, INC. ranks #781 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-3.7Market Cap3B

Estimated Fair Value

$32.7957% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Caution

Bottom half (rank 97%)

Frequently Asked Questions

Is SUPERNUS PHARMACEUTICALS, INC. (SUPN) a good investment?
Based on AlphaStocks' composite analysis, SUPERNUS PHARMACEUTICALS, INC. (SUPN) scores 4.3 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value — the market may be pricing in future growth.
What is SUPERNUS PHARMACEUTICALS, INC.'s Piotroski F-Score?
SUPERNUS PHARMACEUTICALS, INC.'s Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is SUPN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $33, SUPN appears overvalued. The stock currently trades 57% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does SUPN compare to other Health Care stocks?
SUPERNUS PHARMACEUTICALS, INC. ranks #781 out of 1127 stocks in the Health Care sector, placing it in the top 69% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about SUPN?
AlphaStocks evaluates SUPN using five proven investment models. Piotroski: Neutral; Buffett: Neutral; Graham: Caution; Lynch: Attractive; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.3/10.

Similar Stocks

PARRFTIAZN

Compare SUPN with

SUPN vs PARRSUPN vs FTISUPN vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer